Heart & Vascular Institute of Florida is at the forefront in researching new techniques and technologies in fighting heart disease. This experience leads to expertise in providing the most advanced treatment plans and better care options.

ERASE MI- “A Randomized Trial to Evaluate the Effect of Adjunctive Antiplatelet Therapy with Intravenous PRT060128, a Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention in Patients with ST-Elevation Myocardial Infarction.

Sub-Investigator-St. Joseph Mercy Oakland

PLATO- A Study of PLATelet inhibition and Patient Outcomes. “A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for   Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes Sub-Investigator-St. Joseph Mercy Oakland

ASCEND HF- A Study of Heart Failure and Nesiritide. “A Randomized, Double-Blind, Placebo-Controlled, Multicenter Acute Study of  Clinical Effectiveness of Nesiritide in Subjects with  Decompensated Heart Failure.”

Sub-Investigator-St. Joseph Mercy Oakland

IMPROVE IT- IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. “A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome.”

Sub-Investigator-St. Joseph Mercy Oakland

TRA.CER- Thrombin Receptor Antagonist for Clinical Event in Acute Coronary Syndrome. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome.”

Sub-Investigator- Henry Ford Hospital/ St. Joseph Mercy Oakland

CRECENDO- Comprehensive Rimonabant Evaluatiion Cardiovascular ENDpoints and Outcomes. “A Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors.”

Sub-Investigator-St. Joseph Mercy Oakland

XIENCE V- “This prospective, open-label, multi-center, observational, single-arm registry is designed to evaluate clinical outcomes in a cohort of real world patients receiving the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) during commercial use by various physicians with a range of coronary stenting experience.”

Sub-Investigator- Henry Ford Hospital/ St. Joseph Mercy Oakland

Procedures in Trials & Registry

• Watchman Left Atrial Appendage Closure System
• CAP Registry an extension of the PROTECT AF Trial
• Percutaneous Transcatheter Aortic Heart Valve
• PARTNER Trial
• Percutaneous E-Valve MitraClip
• EVEREST II Trial/ Realism Registry
• Impella Recover LP System
• RECOVER II Trial